Overview

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the pharmacokinetics and safety of WAL2014 capsules administered orally as a single dose to healthy adult male volunteers in double blind manner.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim